# Study to Nivolumab Following Preoperative Chemoradiotherapy

> **NCT02948348** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Takayuki Yoshino** · enrollment: 90 (estimated)

## Conditions studied

- Cancer of Rectum

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT02948348
- **Lead sponsor:** Takayuki Yoshino
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2021-12
- **Final completion:** 2022-08
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2021-09-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02948348

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02948348, "Study to Nivolumab Following Preoperative Chemoradiotherapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02948348. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*